Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Pharmaceutical companies have found themselves in the cross hairs of both plaintiffs' lawyers and prosecutors. As a consequence of their sales and marketing practices, these companies have been civilly and criminally fined hundreds of millions of dollars. Meanwhile, the plaintiff's bar is persistently poised to file civil actions almost simultaneously with news of a potential question involving the safety of a prescription medication.
Background
The U.S. Food and Drug Admin- istration ('FDA') must approve all new drugs and accompanying labeling, including all warnings. When submitting a new drug application ('NDA'), the company provides the FDA with data as to the product's safety and efficacy for the treatment of specific conditions at certain strengths. Should the FDA approve that product, its approval is limited only to those conditions and dosages that have been subjected to rigorous testing. The FDA also approves the product labeling, including the language of all warnings and precautions. Approval of a product for one particular indication does not mean that it cannot be used for some other purpose. A physician is permitted to prescribe a product for any use, regardless of the approved labeling. Such a use is termed an 'off-label' use. A pharmaceutical company may not, however, market its products for off-label uses. Marketing of a product for an off-label use results in the product being deemed misbranded and may subject the company to civil and criminal penalties. Both prosecutors and plaintiffs' lawyers are paying close attention to those companies that engage in off-label promotion, particularly where direct-to-consumer advertisements expressly or implicitly promote a product for an off-label use.
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
This article highlights how copyright law in the United Kingdom differs from U.S. copyright law, and points out differences that may be crucial to entertainment and media businesses familiar with U.S law that are interested in operating in the United Kingdom or under UK law. The article also briefly addresses contrasts in UK and U.S. trademark law.
The Article 8 opt-in election adds an additional layer of complexity to the already labyrinthine rules governing perfection of security interests under the UCC. A lender that is unaware of the nuances created by the opt in (may find its security interest vulnerable to being primed by another party that has taken steps to perfect in a superior manner under the circumstances.
With each successive large-scale cyber attack, it is slowly becoming clear that ransomware attacks are targeting the critical infrastructure of the most powerful country on the planet. Understanding the strategy, and tactics of our opponents, as well as the strategy and the tactics we implement as a response are vital to victory.
Possession of real property is a matter of physical fact. Having the right or legal entitlement to possession is not "possession," possession is "the fact of having or holding property in one's power." That power means having physical dominion and control over the property.
In Rockwell v. Despart, the New York Supreme Court, Third Department, recently revisited a recurring question: When may a landowner seek judicial removal of a covenant restricting use of her land?